Q Chip: Tim Sparey. Developing the next generation of sustained-release drug formulations.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Q Chip: Tim Sparey. Developing the next generation of sustained-release drug formulations.
Released on: August 02, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Q Chip's CEO, Tim Sparey talks about the Cardiff based company's lead programme Q-Octreotide and how it has the potential to improve upon the standard of care for acromegaly patients.
  • Summary
  • Transcript
  • Participants
  • Company
Q Chip's CEO, Tim Sparey talks about the Cardiff based company's lead programme Q-Octreotide and how it has the potential to improve upon the standard of care for acromegaly patients.
Q Chip's CEO, Tim Sparey talks about the Cardiff based company's lead programme Q-Octreotide and how it has the potential to improve upon the standard of care for acromegaly patients.
Tim Sparey
Q Chip
Q Chip
Q Chip Ltd, incorporated in 2003, is a specialist drug delivery company based in Cardiff, UK. We are experts in the application of fluidic droplet systems (including microfluidic and piezo-based platforms) to formulate monodispersed microspheres for the controlled release of APIs. The Q-Sphera Microsphere production platform was developed in response to the limitations of current microsphere manufacturing methods and delivers consistent, reproducible and highly efficient production of microspheres whilst providing control over burst release and subsequent zero order drug delivery. Q Chip’s lead programme is Q-Octreotide. This is a 30 day Octreotide acetate depot formulation, which has the potential to improve upon the standard of care for acromegaly patients. Our formulation begins to steadily release octreotide immediately, i.e. without a lag phase. Further, bioavailability is markedly increased (compared to marketed product). Production of clinical trial material is in progress, and scheduled to enter clinic in Q1 2014.